JaZITIN

Manufacturer:
Rusan Pharma(India)

Latin name, the name of the manufacturer:
Yazitin

Group affiliation:
H2-gistaminovh receptors antagonist

The active ingredient of ATC:
A02BA02 Ranitidine

Pharmaceutical form:
injection, tablets film-coated

Application:
After consultation with the doctor

Pharmacological action

Antiulcer. Selectively blocking gistaminove H2-receptors. Suppress basal and stimulirovannuyu secretion of hydrochloric acid, reduces the volume and acidity gastric juice. Duration of dose 150 mg orally 12 hours of rapidly absorbed from the digestive tract.. The maximum concentration is achieved through 2 o'clock. Passes through gistogematicalkie barriers, incl. the placental, bad-GEB. Partly biotransformiroetsa in the liver and demetiliruetsa. Half-life in normal creatinine clearance is 2-3 o'clock, under reduced- 8-9 hours. The urine through the 24 hours unchanged to return about 30% oral and 70% in/in the imposed dose. Fairly significant concentrations in breast milk. The speed and extent of elimination little dependent on the State of the liver and related mainly to renal function.

Testimony

Peptic ulcer and duodenal, NSAID-gastropathy, postoperative ulcer, reflux esophagitis, Zollinger-Ellison Syndrome, chronic neuralgia with epigastralnami zagrudinnami and pains pain; preventing stress ulcers, recurrent bleeding, Mendelson's syndrome.

Contraindications

Hypersensitivity, cirrhosis with portosystemic encephalopathy in history, the liver and kidneys, pregnancy, lactation, Children up to age 14 years.

Side effects

Headache, dizziness, vertigo, drowsiness, alarm, excitation, depression, hallucinations, obratimaya vagueness of view, involuntary movements, Arrhythmia (tachycardia, bradycardia, asistolija, OF блокада, arrythmia), constipation or diarrhea, nausea, vomiting, abdominal pain, pancreatitis, hepatocellular, holetsaticalkie or mixed hepatitis with jaundice or without it, arthralgia and myalgia, increased creatinine in the blood, leukopenia, granulocytopenia, thrombocytopenia, agranulocytosis, pancytopenia, gipoplasia bone marrow and aplastic anemia, immune hemolytic anemia, gynecomastia, impotence, decreased libido, alopecia, rash, erythema multiforme, angioedema, anaphylaxis.

Dosing and Administration

Adult. Parenteral. Intravenously (I /) slowly during 2 m 50 mg in saline solution to 20 ml; If necessary, conduct refresher introduction every 6-8 h; in/in drip speed 25 mg/h for 2 h; if necessary – Re-introduction 6-8 no. Intramuscularly – 50 mg 3-4 times / day. For the prevention of bleeding from stress ulcers in seriously ill patients cli prevention recidivating bleeding in patients with ulcers stomach and duodenal ulcers appoint dropped so far, While the patient cannot eat. Patients with persistent risk of bleeding later on assign product inside 150 mg 2 times / day. For the prevention of bleeding from the upper gastrointestinal tract (GI) stress ulcer in patients with preferably a drug in/in slowly in the initial dose of 50 mg followed by continuous intravenous infusion 0.125-0.25 mg / kg / hr. Patients at risk for aspiration of acidic appoint 50 mg in/m or/in slowly over the 45-60 minutes before general anesthesia. Enterally. Ulcers disease duodenal and benign gastric ulcers in the phase of deterioration, postoperative ulcer – 150 mg 2 times / day or 300 mg per night for 4 weeks. In patients with unhealed sores within that period – continued treatment during the next 4 weeks. Relapse prevention – 150 mg at night; for smokers – 300 mg at night. NSAID-gastropathy – 150 mg 2 times / day or 300 mg at night for 8-12 weeks; prevention – by 150 mg 2 times / day. Erosive reflux esophagitis – 150 2paza mg/day or 300 mg at night for 8 weeks, If necessary treatment extend to 12 weeks. In II and III of art. the severity of reflux-esophagitis dose increase to 600 mg / day 4 reception within 12 weeks. Long-term preventative therapy – 150 mg 2 times / day. For relief of pain – l50 mg 2 times/day for 2 weeks. With the ineffectiveness of treatment can be continued at the same dose over the next 2 weeks. Zollinger-Ellison Syndrome – the initial dose 150 mg 3 times / day, if necessary – 6 g / day. Chronic episodes dispepsii ranitidine appoint 150 mg 2 times / day for 6 weeks. To prevent bleeding from stress ulcers, recidivating bleeding in patients with gastroduodenal izgyazwleniami parenteral treatment can be replaced by oral appointment of drug dose 150 mg 2 times / day, as soon as you start eating patients through the mouth. To prevent the development of Mendelssohn syndrome – 150 mg for 2 hours before narcosis and the night before. Delivery during childbirth appoint 150 mg every 6 no. Children. For the treatment of peptic ulcer – 2-4 mg / kg 2 times / day; the maximum daily dose – 300 mg. Patients with impaired renal function requires correction mode. When creatinine clearance (CC) less 50 mL/min when injecting introduction – 25 mg, When oral admission – 150 mg / day. Patients, in gemodialise shall appoint another dose immediately after hemodialysis.

Cautions

To apply caution in patients with impaired renal function, with Porphyria (history) and in children. Before treatment, exclude malignant tumors in the stomach and duodenum. In elderly patients with impaired liver or kidney disorder may (confusion) consciousness, makes the need to reduce the dose. Quick-dissolving tablets contain sodium, What to consider when appointing patients, which restricts its reception, and aspartame, undesirable for patients with phenylketonuria.

Cooperation

Antatsida and sukralfat may reduce absorption. Modifies the absorption and excretion of other drugs.